Dr. Keith L. Sellers, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 59 Carothers Rd, Newport, KY 41071 Phone: 859-491-1010 Fax: 859-292-3362 |
Wing Eyecare Optometrist Medicare: Not Enrolled in Medicare Practice Location: 142 Pavilion Pkwy, Newport, KY 41071 Phone: 859-291-9464 |
Dr. Jacob Anthony Michael, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 142 Pavilion Pkwy, Newport, KY 41071 Phone: 859-291-9464 Fax: 859-291-3222 |
National Vision Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 64 Carothers Rd, Newport, KY 41071 Phone: 859-486-2831 |
Kelli Bruce, OD Optometrist Medicare: Medicare Enrolled Practice Location: 59 Carothers Rd, Newport, KY 41071 Phone: 859-491-1010 |
Myeyedr. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 142 Pavilion Pkwy, Newport, KY 41071 Phone: 859-291-9464 Fax: 859-291-3222 |
Dr. Elizabeth Walsh Czirr, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1400 Grand Ave, Newport, KY 41071 Phone: 859-781-3110 Fax: 859-441-1418 |
Opticare Vision Center Optometrist Medicare: Medicare Enrolled Practice Location: 59 Carothers Rd, Newport, KY 41071 Phone: 859-491-1010 Fax: 859-292-3362 |
News Archive
John T. Spitznagel of Glen Burnie, Maryland is a lifetime member of America's Registry of Outstanding Professionals. He has been selected as the Industry Leader of the Month of July 2015 for his accomplishments in the field of Healthcare Sales and Marketing.
Weight loss mobile applications may work well as basic tracking devices, but need to do more to help dieters improve motivation, reduce stress and solve problems, according to a new report in the American Journal of Preventive Medicine.
In recent years, researchers have worked to develop more flexible, functional prosthetics for soldiers returning home from battlefields in Afghanistan or Iraq with missing arms or legs. But even new prosthetics have trouble keeping bacteria from entering the body through the space where the device has been implanted.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has completed enrollment in a Phase 1 study of KAI-4169, a novel pharmaceutical agent for the treatment of secondary hyperparathyroidism, which is a frequent complication of end stage renal disease.
› Verified 6 days ago